Evidence map›Paper›PMID 35330385›Full record

ArticleJournal of personalized medicine2022

Reducing the Excess Activin Signaling Rescues Muscle Degeneration in Myotonic Dystrophy Type 2

Jing Deng, Xin-Xin Guan, Ying-Bao Zhu, Hai-Tao Deng, Guang-Xu Li, Yi-Chen Guo, Peng Jin, Ran-Hui Duan, Wen Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Decoding Nucleotide Repeat Expansion Diseases: Novel Insights fromInternational journal of molecular sciences · 2024
    Review
  2. Modeling Myotonic Dystrophy Type 2 UsingInternational journal of molecular sciences · 2023
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jing DengCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Xin-Xin GuanCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Ying-Bao ZhuCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Hai-Tao DengCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Guang-Xu LiCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Yi-Chen GuoCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Peng JinDepartment of Human Genetics, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Ran-Hui DuanCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Wen HuangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410017, China.
Central South University · CNEmory University · USYueyang Hospital · CN

Funding

Changsha Municipal Natural Science Foundation kq2007073Hunan Provincial Natural Science Foundation 2016JJ3135Hunan Science and Technology major project of Birth Defect cooperative control 2019SK1010National Natural Science Foundation of China 81571253National Natural Science Foundation of China 81771385National Natural Science Foundation of China 82071273National Natural Science Foundation of China 82101958
6 · The paper itself

Abstract

Expanded non-coding RNA repeats of CCUG are the underlying genetic causes for myotonic dystrophy type 2 (DM2). There is an urgent need for effective medications and potential drug targets that may alleviate the progression of the disease. In this study, 3140 small-molecule drugs from FDA-approved libraries were screened through lethality and locomotion phenotypes using a DM2

Indexed as

chemical screenDrosophilamyotonic dystrophy type 2TGF-β pathway

Identifiers

PMID35330385
PMCPMC8948895
OpenAlexW4214810221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.